T0504-7238 | 104411-59-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: T0504-7238
• 英文别名: 3-Chloro-2-morpholin-4-yl-6-morpholin-4-ylsulfonylnaphthalene-1,4-dione
• CAS: 104411-59-8
• 化学式: C₁₈H₁₉ClN₂O₆S
• 分子量: 426.878
• InChiKey: VRUFVMALYTYKOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  T0504-7238 、 氨 生成 2-amino-3-chloro-6-morpholin-4-ylsulfonylnaphthalene-1,4-dione
  参考文献：
  名称：

  SHISHKINA, R. P.;MAMATYUK, V. I.;EHKTOVA, L. V.;FOKIN, E. P., IZV. AN CCCP. CEP. XIM., 1985, N 11, 2524-2530

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3-dichloro-1,4-naphthoquinone-6-sulfonylmorpholide 、 吗啉 生成 T0504-7238
  参考文献：
  名称：

  SHISHKINA, R. P.;MAMATYUK, V. I.;EHKTOVA, L. V.;FOKIN, E. P., IZV. AN CCCP. CEP. XIM., 1985, N 11, 2524-2530

  摘要：

  DOI：

文献信息

• Reaction of 6-sulfonyl-2,3-dichloro-1,4-naphthaquinones with nucleophilic reagents
  作者：R. P. Shishkina、V. I. Mamatyuk、L. V. �ktova、E. P. Fokin

  DOI：10.1007/bf00956796

  日期：1985.11
• Compound with Anti-Cancer Properties
  申请人：Velgene 3 Limited

  公开号：US20160339036A1

  公开（公告）日：2016-11-24

  The invention relates to blocking autophagy in the treatment or prevention of various forms of cancer by using the compounds of the invention or their pharmaceutically acceptable salts. Also described are pharmaceutical compositions comprising the compounds of the invention or pharmaceutically acceptable salts thereof. Pharmaceutical compositions may be formulated as, but not limited to, tablets, capsules, solutions and ointments. The invention further relates to suitable pharmaceutical compositions, which contain the compounds of the invention as a combined preparation for simultaneous, separate or sequential use for the treatment and prevention of cancer.
• [EN] COMPOUND WITH ANTI-CANCER PROPERTIES<br/>[FR] COMPOSÉ AYANT DES PROPRIÉTÉS ANTICANCÉREUSES
  申请人：VELGENE 3 LTD

  公开号：WO2015079068A1

  公开（公告）日：2015-06-04

  The invention relates to blocking autophagy in the treatment or prevention of various forms of cancer by using the compounds of the invention or their pharmaceutically acceptable salts. Also described are pharmaceutical compositions comprising the compounds of the invention or pharmaceutically acceptable salts thereof. Pharmaceutical compositions may be formulated as, but not limited to, tablets, capsules, solutions and ointments. The invention further relates to suitable pharmaceutical compositions, which contain the compounds of the invention as a combined preparation for simultaneous, separate or sequential use for the treatment and prevention of cancer.
• SHISHKINA, R. P.;MAMATYUK, V. I.;EHKTOVA, L. V.;FOKIN, E. P., IZV. AN CCCP. CEP. XIM., 1985, N 11, 2524-2530
  作者：SHISHKINA, R. P.、MAMATYUK, V. I.、EHKTOVA, L. V.、FOKIN, E. P.

  DOI：——

  日期：——